Cytosorbents Corporation filings document the company's public reporting as a Nasdaq-listed medical technology issuer with common stock registered under Section 12(b). Recent Form 8-K filings furnish results of operations and financial condition, press release exhibits, Regulation FD disclosures, and other event reports tied to the company's blood purification business.
The filing record also documents regulatory disclosure categories for DrugSorb®-ATR, including FDA and Health Canada communications, De Novo market authorization matters, and related supervisory review or reconsideration processes. Other filings address Nasdaq continued-listing compliance under minimum bid price rules, credit-facility and balance-sheet disclosures reported with earnings releases, and the exhibits that support material corporate updates.
CytoSorbents Corporation (CTSO) regained compliance with Nasdaq’s $1.00 minimum bid-price requirement after its closing bid price was at least $1.00 for 10 consecutive trading sessions ending September 21, 2026. Nasdaq notified the company on September 22 that the matter was closed.
A separate listing requirement remains: CytoSorbents received notice on June 29, 2026, that the market value of its listed securities was below $35 million. The company has until December 28, 2026 to regain compliance; market value must meet or exceed $35 million for 10 consecutive business days, unless Nasdaq staff extends the period. The company is evaluating potential actions and may consider alternatives, including stockholders’ equity of at least $2.5 million. If it has not regained compliance by the deadline, Nasdaq will notify it that its securities are subject to delisting, and the company may appeal. CytoSorbents said there is no assurance it will regain compliance or maintain its Nasdaq listing. The company also identified driving CytoSorb sales, achieving operating cash flow breakeven in the second half of 2026, advancing DrugSorb-ATR toward FDA regulatory approval, and unlocking the strategic value of HemoDefend-BGA as priorities.
Cytosorbents Corp (CTSO) reporting person Phillip P. Chan, Chief Executive Officer and director, purchased 3,774 shares of Common Stock in an open market transaction on September 15, 2026 at $6.00 per share, and now directly holds 100,996 shares of Common Stock, including restricted stock units.
The holdings include several tranches of RSUs that vest upon a "Change In Control" or over time under the company’s 2014 Long-Term Incentive Plan, as well as 83,782 shares of Common Stock. The share amounts reflect the 1-for-20 reverse stock split effected on September 8, 2026. No Rule 10b5-1 trading plan is reported.
Cytosorbents Corp (CTSO) reports that President and COO Vincent Capponi purchased Common Stock in open-market transactions on September 14, 2026, buying 1,800 shares at $6.07 per share and 273 shares at $5.90 per share, with no Rule 10b5-1 trading plan reported.
Capponi’s reported holdings include multiple tranches of RSUs that settle into Common Stock upon a Change in Control under the 2014 Long-Term Incentive Plan, time-based RSUs including 4,455 RSUs granted August 8, 2025 (2,228 unvested), and 25,736 shares of Common Stock owned, all figures reflecting the 1-for-20 reverse stock split effective September 8, 2026.
Cytosorbents Corp (CTSO) director Alan D. Sobel reported open-market purchases of company common stock on September 15, 2026. He bought a total of 2,500 shares in three transactions at prices between $6.01 and $6.12 per share. No Rule 10b5-1 trading plan is reported for these purchases. His equity interests also include restricted stock units that vest upon a Change in Control under the company’s 2014 Long-Term Incentive Plan and 6,422 shares of common stock owned directly, all reflecting a previously effected 1-for-20 reverse stock split.
Cytosorbents Corp (CTSO) reports that Chief Executive Officer and director Phillip P. Chan purchased 200,000 shares of Common Stock on September 4, 2026, in an open-market transaction at a weighted average price of $0.35 per share, with individual trades ranging from $0.3470 to $0.3599.
Following this purchase, Chan holds a reported total of 1,944,432 shares, consisting of Common Stock and restricted stock units that vest upon specified conditions, and the report notes that these amounts were not adjusted for a reverse stock split that occurred on September 8, 2026; no Rule 10b5-1 trading plan is reported.
CytoSorbents Corporation (CTSO) implemented a 1-for-20 reverse stock split of its common stock, effective at 12:01 a.m. E.T. on September 8, 2026. As of September 3, 2026, there were 63,022,020 shares of common stock outstanding that became subject to this reclassification.
Every twenty previously issued and outstanding shares of common stock were automatically reclassified into one share, with no change to the $0.001 par value and no change to the total number of authorized shares. Fractional entitlements were rounded up to the nearest whole share, and outstanding options and warrants were proportionately adjusted in both share amount and exercise price. Trading continues on Nasdaq on a split-adjusted basis under CTSO, with a new CUSIP of 23283X305.
CytoSorbents Corporation held its 2026 Annual Meeting of Stockholders on August 13, 2026. Stockholders representing 42,487,327 of 62,842,748 outstanding common shares were present in person or by proxy, constituting a quorum. Five directors, including Dr. Phillip P. Chan, were elected with support levels generally above 23.6 million votes in favor for each nominee, with substantial broker non-votes recorded.
On a non-binding, advisory basis, compensation of named executive officers received 21,831,424 votes for, 2,988,267 against, and 2,642,933 abstentions. Stockholders ratified WithumSmith+Brown, PC as independent registered public accounting firm for 2026 with 41,517,193 votes for. They also approved a charter amendment authorizing a reverse stock split at a ratio between 1-for-5 and 1-for-20, to be implemented at the Board’s discretion within one year of the meeting, and approved a potential adjournment proposal, though no adjournment was needed.
CytoSorbents Corporation furnished an investor presentation outlining Q2 2026 performance and strategic priorities. Product revenue was $9.6 million, flat year over year, with growth from distributors and strategic partners and direct international sales offset by lower German revenue following a salesforce restructuring. Gross margin improved to 73%, total operating expenses declined to $9.7 million from $10.4 million, and operating loss narrowed to ($2.6 million). Reported net income was $1.9 million, or $0.03 per share, compared with a $4.4 million loss a year earlier, while adjusted net loss was ($2.9 million) and adjusted EBITDA loss ($1.6 million). Cash, cash equivalents and restricted cash totaled $5.9 million with net operating cash burn of about $0.4 million in Q2, including $0.2 million of restructuring payments; management continues to target operating cash flow breakeven in the second half of 2026.
Management highlights four value drivers: achieving operating cash flow breakeven, returning core CytoSorb sales to growth, opening the U.S. market with DrugSorb-ATR, and unlocking the value of HemoDefend-BGA. Trailing twelve-month core product sales reached $37.3 million as of June 30, 2026, with more than 300,000 CytoSorb treatments performed in over 70 countries. For DrugSorb-ATR, the pivotal STAR-T trial showed a 58% risk reduction and 16.3% absolute reduction in major bleeding (NNT=6) despite missing its primary endpoint, leading to an FDA De Novo denial. On appeal, FDA raised no major safety concerns, indicated a new large trial is not required, and invited a focused new De Novo submission supported by additional mechanistic data and real-world evidence from European use. The company is also exploring a parallel De Novo pathway for direct oral anticoagulant removal. HemoDefend-BGA, a gravity-driven filter to create universal plasma and blood products, has been developed with more than $16 million in non-dilutive government funding; the company recently received constructive FDA feedback on a planned clinical pathway and is preparing for clinical trials while positioning the asset for potential partnerships, licensing, or other strategic options.
CytoSorbents Corporation reported second quarter 2026 net revenue of $9,633k, compared with $9,617k a year earlier, with product gross margin rising to 73%. Operating expenses were $9,687k, yielding a loss from operations of $2,638k and a net loss of $4,417k versus net income of $1,947k in the prior-year quarter. Adjusted EBITDA improved to a loss of $1,649k from a $2,640k loss, and operating cash burn fell to about $200k excluding restructuring payments. Since September 2025 the workforce has been reduced by approximately 23% to create a leaner organization.
As of June 30, 2026, cash and cash equivalents totaled $4,413k, restricted cash $1,522k, total assets $37,960k, and stockholders’ equity was a deficit of $751k driven by an accumulated deficit of $321,754k. Management highlighted four value drivers over the next 6–18 months: achieving sustainable operating cash flow breakeven, returning the CytoSorb franchise to profitable growth, pursuing FDA De Novo submissions and potential marketing authorization for DrugSorb-ATR in a U.S. and Canada market estimated at $500 million to $1 billion, and realizing the strategic value of HemoDefend-BGA, developed with roughly $16 million of prior non-dilutive U.S. government funding.
CytoSorbents Corporation reported Q2 2026 revenue of $9.6 million, essentially flat year over year, with gross margin improving to 73.2%. Loss from operations narrowed to $2.6 million, but a foreign‑currency loss and higher interest drove a net loss of $4.4 million versus prior‑year profit.
Cash, cash equivalents and restricted cash totaled $5.9 million at June 30, 2026, compared with $18.4 million of Avenue Capital term debt due in 2027. Management states that these cash levels, debt obligations and expected cash use raise substantial doubt about the company’s ability to continue as a going concern over the next 12 months.
Operating expenses declined, aided by a Strategic Workforce and Cost Reduction Plan that reduced headcount by about 23% and generated approximately $0.3 million of Q2 restructuring charges. The company continues to pursue U.S. FDA De Novo clearance for its DrugSorb‑ATR antithrombotic removal system, now targeting a new submission in early 2027.